AU2019322858A1 - Combination therapy - Google Patents

Combination therapy Download PDF

Info

Publication number
AU2019322858A1
AU2019322858A1 AU2019322858A AU2019322858A AU2019322858A1 AU 2019322858 A1 AU2019322858 A1 AU 2019322858A1 AU 2019322858 A AU2019322858 A AU 2019322858A AU 2019322858 A AU2019322858 A AU 2019322858A AU 2019322858 A1 AU2019322858 A1 AU 2019322858A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
solvate
hydrate
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019322858A
Other languages
English (en)
Inventor
Daniel P. Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lite Strategy Inc
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of AU2019322858A1 publication Critical patent/AU2019322858A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019322858A 2018-08-14 2019-08-13 Combination therapy Abandoned AU2019322858A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862718925P 2018-08-14 2018-08-14
US62/718,925 2018-08-14
PCT/US2019/046405 WO2020036995A1 (en) 2018-08-14 2019-08-13 Combination therapy

Publications (1)

Publication Number Publication Date
AU2019322858A1 true AU2019322858A1 (en) 2021-04-01

Family

ID=69525833

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019322858A Abandoned AU2019322858A1 (en) 2018-08-14 2019-08-13 Combination therapy

Country Status (9)

Country Link
US (1) US20210161909A1 (https=)
JP (1) JP2021534114A (https=)
CN (1) CN112839651A (https=)
AU (1) AU2019322858A1 (https=)
EA (1) EA202190360A1 (https=)
IL (1) IL280729A (https=)
MX (1) MX2021001764A (https=)
TW (1) TW202021592A (https=)
WO (1) WO2020036995A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
AU2023228576A1 (en) * 2022-03-01 2024-09-26 Mei Pharma, Inc. Combination therapy of pi3k inhibitor and pd-1 inhibitor
CN118949002A (zh) * 2024-10-15 2024-11-15 杭州阿克索生物科技有限责任公司 一种宫颈癌细胞抑制组合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563596B2 (en) * 2006-06-21 2013-10-22 Piramal Enterprises Limited Enantiomerically pure compounds for the treatment of proliferative disorders
ES2608967T3 (es) * 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
WO2014055647A1 (en) * 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
TW201618773A (zh) * 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
RU2726367C2 (ru) * 2016-03-28 2020-07-13 Пресидж Байосайенсиз, Инк. Фармацевтические комбинации для лечения злокачественной опухоли
CN109982687A (zh) * 2016-09-19 2019-07-05 梅制药公司 联合疗法
US11304953B2 (en) * 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
KR20200041358A (ko) * 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법

Also Published As

Publication number Publication date
MX2021001764A (es) 2021-04-19
IL280729A (en) 2021-03-25
WO2020036995A1 (en) 2020-02-20
CN112839651A (zh) 2021-05-25
US20210161909A1 (en) 2021-06-03
EA202190360A1 (ru) 2021-07-15
JP2021534114A (ja) 2021-12-09
TW202021592A (zh) 2020-06-16

Similar Documents

Publication Publication Date Title
US20210000838A1 (en) Combination therapy
AU2017326558B2 (en) Combination therapy
US11351176B2 (en) Combination therapy
US12161644B2 (en) Combination therapy
WO2020132563A1 (en) Combination therapy
AU2019322858A1 (en) Combination therapy
WO2020036999A1 (en) Treatment of b cell malignancies

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period